Analysis of chimaerism in thalassaemic children undergoing stem cell transplantation

Citation
Pj. Amrolia et al., Analysis of chimaerism in thalassaemic children undergoing stem cell transplantation, BR J HAEM, 114(1), 2001, pp. 219-225
Citations number
18
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
BRITISH JOURNAL OF HAEMATOLOGY
ISSN journal
00071048 → ACNP
Volume
114
Issue
1
Year of publication
2001
Pages
219 - 225
Database
ISI
SICI code
0007-1048(200107)114:1<219:AOCITC>2.0.ZU;2-3
Abstract
We have prospectively assessed the relative contribution of host and donor to haemopoiesis following stem cell transplantation (SCT) in children with beta -thalassaemia major (n = 35), using karyotype analysis or Southern blo t/polymerase chain reaction analysis of variable number tandem repeats on g enomic DNA from peripheral blood. Early haemopoiesis was fully donor in ori gin in 24 out of 35 cases and remained so throughout the post-transplant co urse in all but one patient, who evolved to stable mixed chimaerism. The re maining 11 cases (31%) initially showed mixed chimaerism: four of these rej ected, one eventually eradicated host haemopoiesis to become fully donor ha emopoietic, and the remaining six had persistent mixed chimaerism, with 5-3 8% host haemopoiesis. The risk of graft rejection was high when > 15% host haemopoiesis was present at 3 months post transplant: four out of six such patients rejected their grafts; conversely, zero out of 29 patients with < 15% host haemopoiesis at 3 months rejected (P < 0.0001). There was a higher incidence of significant acute and chronic graft-versus-host disease in pa tients with full donor chimaerism. These studies confirm that the mixed chi maeric state is common following SCT for thalassaemia, often persists (with up to 4 years follow-up) and is compatible with long-term cure. Analysis o f chimaerism in patients undergoing SCT for beta -thalassaemia enables moni toring of engraftment in the early post-transplant period, provides insight into the biology of engraftment and may be useful in identifying patients at high risk of rejection.